SCHEMBL5886240

SCHEMBL5886240

O=C(O)c1cccc2nc3ccc4c(O)cccc4c3nc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.59
MYC P01106 1/20 0.47
MAX P61244 1/20 0.47
CDC25B P30305 2/20 0.46
KDM4E B2RXH2 4/20 0.44
RAB9A P51151 2/20 0.44
KDM4A O75164 1/20 0.44
EGLN1 Q9GZT9 1/20 0.44
HIF1AN Q9NWT6 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GRIN2D O15399 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3724658 0.84 ALDH1A1 (0.71) ALDH1A1KDM4ERAB9AKDM4AEGLN1
SCHEMBL30468172 0.84 ALDH1A1 (0.71) ALDH1A1KDM4ERAB9AKDM4AEGLN1
SCHEMBL5886268 0.84 ALDH1A1 (0.58) ALDH1A1KDM4ELMNAKMT2AMEN1
SCHEMBL5886249 0.84 ALDH1A1 (0.58) ALDH1A1MYCKDM4ELMNAMAPT
SCHEMBL5886290 0.84 ALDH1A1 (0.58) ALDH1A1CDC25BKDM4ERAB9AL3MBTL1
SCHEMBL5886331 0.84 ALDH1A1 (0.58) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL5886397 0.84 ALDH1A1 (0.58) ALDH1A1KDM4ELMNANR4A1NR4A2
SCHEMBL5886278 0.83 ALDH1A1 (0.54) ALDH1A1MYCMAXKDM4EL3MBTL1
SCHEMBL5886363 0.83 ALDH1A1 (0.56) ALDH1A1MYCMAXCDC25BKDM4E
SCHEMBL5886475 0.83 ALDH1A1 (0.56) ALDH1A1MYCMAXCDC25BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132419-B2 Pharmaceutical compounds XENOVA LIMITED (GB) 2006-11-07 US claimed
US-20050143383-A1 Pharmaceutical compounds XENOVA LIMITED (GB) 2005-06-30 US claimed
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US claimed
US-7132419-B2 Pharmaceutical compounds XENOVA LIMITED (GB) 2006-11-07 US disclosed
US-20050143383-A1 Pharmaceutical compounds XENOVA LIMITED (GB) 2005-06-30 US disclosed
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143383-A1 Pharmaceutical compounds CHRNA10, OPRM1, SCN10A ALDH1A1 3766/4885MYC 2269/4885MAX 2331/4885
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II TOP1, TOP2A, TOP2B ALDH1A1 2334/4885MYC 1982/4885MAX 3165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.